Equity in Clinical Research: From Trials to Treatment
Many pharmaceutical and medical device companies have made commitments to address health inequities as they exist in the realm of clinical trials. Precision’s Alice Pressman co-authors this article discussing some of the obstacles, solutions, and implications for widespread efforts to improve health equity throughout the clinical research cycle.
Diabetes Cure or Diabetes Management?
Diabetes deaths in the United States continue to surge well above pre-pandemic levels with over 100,000 Americans dying from diabetes in 2021. Increasing deaths from diabetes is a clear call to action for new solutions. Historically, diabetes has been treated as a chronic disease, managed with a lifetime of medications. However, a new line of thinking about diabetes remission permeates the literature.
Miss any of our Recent Precision Value & Health Events? Check out our June Events Calendar
Miss any of our recent Precision Value & Health events? Check out our monthly marketing activities calendar to catch up on-demand, and stay ahead of upcoming dates!
CMS Rule on Pharma Patient-Assistance Programs Could Cut Back on Aid
A rule slated to take effect January 1, 2023 would reverse CMS’ long held position that manufacturer-provided assistance given to patients is excluded from best price and average manufacturer price calculation for prescription drugs. The rule change could potentially result in increased patient out-of-pocket costs for drugs and pharma companies being on the hook for ensuring they know exactly where their assistance is going.
Big Data Analytics in Health Care and Drug Therapy Management—Opportunities and Considerations
Modern technology allows for the mass collection of digital health data. Artificial intelligence has become a vital tool for making sense of the huge volume of health data being collected daily through the use of big data analytics (BDA).
ISPOR 2022
Are you attending ISPOR May 15-18 in Washington, DC? Don’t miss any of the Precision workshops and poster presentations.
Two Key Questions About Payer Strategies in 2022
Want to know the optimal strategies for negotiating pricing and formularies, and how the industry is adjusting to the continued push toward value-based models? Precision’s Ryan Cox and other experts weigh in.
CMS Targets Patient-Assistance Programs; Rule Could Curtail Aid
CMS’s stance has long been that manufacturer-provided assistance given to patients is excluded from best price and average manufacturer price calculation for prescription drugs. However, the rise of copayment accumulators and maximizers and health insurers’ subsequent taking of this assistance rather than allowing it to count toward patients’ deductibles and out-of-pocket maximums have caused the agency to rethink its position. Precision’s Ryan Cox and Reta Mourad break down the implications of the proposed rule change, including the potential for increased patient out-of-pocket drug costs, pharma companies being on the hook for ensuring they know exactly where their assistance is going, and possible unintended consequences.
Conference: Meeting on the Med, 2022
Precision will be at this year’s Meeting on the Med conference from April 20 – 22nd in Barcelona, Spain. Connect with our team of experts as they lead meaningful discussions throughout this event, providing insights into the clinical development, manufacturing, and commercialization of cell and gene therapies.
